Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718
In the 14-day open-label study of patients with HD, the safety, tolerability, and pharmacokinetic profile of daily SAGE-718 oral solution were evaluated in six patients with early HD. In the study, SAGE-718 was well tolerated, with no serious adverse events or adverse events leading to treatment discontinuation. In addition, patients demonstrated improved performance, compared to baseline, on assessments of executive functioning, with measures relevant to the core cognitive decline seen in people with HD. These results are comparable to improvements in measures of executive function observed in an earlier Phase 1 cohort of individuals without HD. Additional data from the Phase 1 open-label cohort study on the safety and tolerability of SAGE-718 in patients with early HD will be presented at a future congress in 2020.
In addition, the Company is presenting data from three other non-clinical and Phase 1 studies with SAGE-718 at the 58th Annual Meeting of the
“There is a critical need for better therapeutics to help patients with cognitive decline, particularly those suffering from conditions such as Huntington’s disease,” said
Data presentations at ACNP focus on additional studies in HD, including SAGE-718 data:
Poster [M-147]: Cognitive Deficits in Huntington’s Disease and Altered 24(S)-hydroxycholesterol
24(S)-hydroxycholesterol (24(S)-HC) is an endogenous, brain-specific, cholesterol metabolite that acts as a PAM of the NMDA receptor. Previous work has established that levels of 24(S)-HC are decreased in the plasma and brain in people with HD.
- In this study, plasma samples from the TRACK-HD study, a longitudinal observational study of biological and clinical manifestations of HD, were analyzed.
- Results demonstrated levels of 24(S)-HC declined during the transition from pre-manifest to manifest HD, and that levels correlated with performance on tests of executive dysfunction and emotional processing.
- These data support a role for 24(S)-HC in cognitive changes in HD and suggest that NMDA hypofunction may contribute to cognitive impairment in HD.
Poster [M-144]: Using a Multimodal Biomarker Approach to Identify Functional Target Engagement of the Novel NMDA Positive Allosteric Modulator SAGE-718
A suite of three clinical studies was designed to evaluate CNS-target engagement of SAGE-718 by electrophysiology and magnetic resonance imaging (MRI), using a low-dose ketamine challenge paradigm in healthy adults in a placebo controlled cross-over design.
- In these studies, SAGE-718 was generally well tolerated with no serious adverse events or adverse events leading to treatment discontinuation.
- A single dose administration of SAGE-718 (3 mg oral solution) attenuated ketamine-induced changes in functional MRI-derived alterations of blood oxygenation levels (BOLD), including attenuation of ketamine-induced increases of BOLD observed in posterior brain regions and decreases observed in anterior brain regions (n=13).
- In a single-click, auditory evoked potential paradigm, the N100-P200 potential waveform was significantly reduced by ketamine under placebo conditions, but not after administration of SAGE-718 (n=18).
- Results from these studies demonstrate that SAGE-718 had effects on functional imaging in healthy volunteers. SAGE-718 also modulated the effects of ketamine on regional and global measures of resting brain activity. These effects are in line with the presumed mechanism of action of SAGE-718 as an NMDA PAM, which supports the hypothesis of functional engagement of the NMDA receptor.
In a double-blind, placebo-controlled study, the effects of 10-day repeated exposure of SAGE-718 on core cognitive battery were investigated in healthy volunteers. Healthy volunteers (n=40) were randomized to receive either SAGE-718 1 mg (n=19) plus ketamine or placebo (n=21) plus ketamine, and computerized testing was used to measure performance on key cognitive domains, including attention, working memory, processing speed, executive function, and motor reaction time.
- Statistically significant improvements were observed compared to placebo on tests of higher-order working memory (Two-Back Test) and complex problem solving (Groton Maze Test).
- SAGE-718 was generally well tolerated with no serious adverse events or adverse events leading to study withdrawal or discontinuation.
- Improvements in executive performance, as reflected by significant improvements on the Two-Back and Groton Maze tests, suggest that SAGE-718 is potentially distinct from other cognitive-enhancing compounds and supports further investigation of SAGE-718 for the treatment of conditions characterized by states of relative NMDA hypofunction, particularly those manifesting with executive deficits.
About SAGE-718 and NMDA Receptors
SAGE-718 is a novel, oral, first-in-class, oxysterol-based positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors. SAGE-718 is the lead compound from Sage's NMDA modulator platform.
NMDA receptors are glutamate-gated cation channels that play a critical role in the health and regulation of neurons, and are involved in learning, memory and neuroplasticity. Positive modulation of NMDA receptors may have potential benefit in the treatment of conditions associated with NMDA hypofunction and disorders associated with a high prevalence of anti-NMDA antibodies, as well as in disorders associated with reductions in plasma cerebrosterol, such as
Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: our views and expectations regarding our development plans for SAGE-718; our belief in the potential of SAGE-718 in various indications; the potential profile and benefit of SAGE-718; and the goals, opportunity and potential for our other product candidates and business. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may not be successful in our development of SAGE-718 or any of our other current or future product candidates in any indication we are currently pursuing or may in the future pursue; success in earlier clinical trials or nonclinical studies may not be repeated or observed in ongoing or future studies of SAGE-718 or any of our other product candidates; ongoing and future clinical or nonclinical results may generate results that are different than we expect or may not support further development; we may decide that a development pathway for SAGE-718 or any of our other product candidates in one or more indications is no longer feasible or advisable or that the unmet need no longer exists; decisions or actions of the